TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

134 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

128 studies on the map

BOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvilleMolecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoMigraine in Adolescents — Washington University School of Medicine, St LouisA Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring — Pfizer, New YorkResponding With Evidence and Access for Childhood Headaches — University of Alabama at Birmingham Children's of Alabama, BirminghamSupraspinal Processing of Sensory Aspects of Pain — Cincinnati Children's Hospital, CincinnatiA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeRELAXaHEAD for Headache Patients (Phase III) — NYU Langone Health, New YorkA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaEfficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents — National Intrepid Center of Excellence (NICOE), BethesdaMetabolic Profiling of Immune Responses in Immune-mediated Diseases — National Institutes of Health Clinical Center, BethesdaCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaBE WELL With Migraine: Brain Education and WELLness With Migraine — Cambridge Health Alliance - Center for Mindfulness and Compassion, CambridgeRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithStudy to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks — Neurology and Pain Specialty Center /ID# 278508, Aliso ViejoRegistry for Systemic Eczema Treatments — Johns Hopkins University, BaltimoreA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaEmgality for Migraine in Breastmilk — University of California, San Francisco, San FranciscoReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamExternal Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy — https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true, DarienA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyAcceptance and Commitment Therapy to Improve Disability in Chronic Migraine — Brigham and Women's / Faulkner Hospital, BostonA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamCocoa Extract for Migraine Trial — Brigham and Women's Hospital, BostonA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreInvestigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli — University of Minnesota, MinneapolisAimovig Pregnancy Exposure Registry — IQVIA Virtual Site, DurhamNatural History and Genetics of Food Allergy and Related Conditions — National Institutes of Health Clinical Center, BethesdaA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixEndometriosis and Migraine — Washington University School of Medicine, St LouisStudy to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population — Syneos Health (remote site), MorrisvilleA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoFlourish: Exploring the Early Infant Gut Microbiome — Seeding Labs INC, AustinPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine — Flourish - Birmingham, BirminghamA Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine — Children's Mercy, Kansas CityStudy of EVO756 in Adults With Migraine — CA Medical Clinic for Headache, Los AngelesStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleMMA Embolization for Refractory Chronic Migraine — Barrow Neurological Institute at St. Joseph's Hospital, PhoenixTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomChiropractic Care for Episodic Migraine — Osher Center for Integrative Health, Mass General Brigham, BostonCorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry — CorEvitas, LLC, WalthamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockMechanistic Studies of Psilocybin in Headache Disorders — VA Connecticut Healthcare System, West HavenObservational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant — Evidera, a PPD business unit, WilmingtonTopical Treatment for Atopic Dermatitis — Wake Forest University Health Sciences, Winston-SalemObservational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy — Iqvia /Id# 266904, DurhamThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynMichigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project — University of Michigan, Ann ArborAssessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA — Brown University, ProvidenceA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoA Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyStimulation of External Carotid Artery Circulation — University of Texas Medical Branch, GalvestonStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. — Pfizer, New YorkA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgLight Exposure, Migraine Outcomes, and Sleep Quality — ASU DeSmart Lab, TempeReal-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine — University of Miami, Miller School of Medicine, MiamiBilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine — Johns Hopkins Medicine, BaltimoreEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, PhoenixBilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines — Neuroscience Institute at Great Neck, Great NeckA Comprehensive Digital Care Program for Migraine Management — Hinge Health, Inc., San FranciscoStudy Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients — Sunwise Clinical Research, Llc, Walnut CreekA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Mayo Clinic Hospital, PhoenixBlood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research — University of Pittsburgh Medical Center, PittsburghA Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults — Central Research Associates, BirminghamSkin Microbial Ecology in Atopic Dermatitis — University of Rochester Medical Center, RochesterAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis — Syneos Health (remote site), MorrisvilleMechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism — Boston Children's Hospital, BostonA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Yale-New Haven Children's Hospital - PIN, New HavenA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine — Yale University School of Medicine, New HavenMind Body Intervention for Chronic Migraine Headaches — Beth Israel Deaconess Medical Center, BostonA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideThis Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment — Cahaba Dermatology & Skin Health Center- Site Number : 8400006, BirminghamStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamEvaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares — U.S. Dermatology Partners, PhoenixMonitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT — University of California San Diego (UCSD), La JollaA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamDoes Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs? — University Medical Center of El Paso, El PasoStudies of Skin Microbes in Healthy People and in People With Skin Conditions — National Institutes of Health Clinical Center, BethesdaEffects of Treatments on Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaAnalysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics — Stanford University School of Medicine, StanfordObjectively Diagnose and Monitor Treatment of Light Sensitivity — University of Iowa Health Care, Iowa CityAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) — Regeneron Research Site, BostonRandomized Study in Children and Adolescents With Migraine: Acute Treatment — Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, BirminghamMind Body Balance for Pediatric Migraine — University of Colorado/Children's Hospital Colorado, AuroraLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Perseverance Research Center, LLC, ScottsdaleQudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old — Upsher-Smith Clinical Trial Site #5, BirminghamUnhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research — Brain Inflammation Collaborative, DelafieldClinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain — Peter H Hwang, StanfordUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorDetermining the Utility of a Behavioral Intervention in Chronic Migraine — Mayo Clinic, PhoenixNIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder — National Institutes of Health Clinical Center, BethesdaA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Rehabilitation & Neurological Services /ID# 248517, HuntsvilleEfficacy of Nerve Blocks for Episodic Migraine — Mayo Clinic in Rochester, RochesterOverlapping Pain Trajectory Study — Cincinnati Children's Hospital, CincinnatiInvestigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo) — University of Michigan, Ann ArborA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamComparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study — Northern Arizona Healthcare, FlagstaffA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine — Arkansas Children's Hospital, Little RockA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, Chandler